(Q34116562)

English

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

0 references

1 reference

Europe PubMed Central

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

phase II clinical trial

0 references

phase III clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

David Cunningham

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

author name string

J Zalcberg

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

J Maroun

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

R James

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

S Clarke

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

T S Maughan

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

M Vincent

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

J Schulz

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

M González Barón

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

T Facchini

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 March 2002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

38

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

478-486

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Which 5-fluorouracil regimen?--the great debate.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900413-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(01)00413-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872339%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34116562&oldid=1412729289"